A Q&A with Amyn Hassanally, a partner and global head of private equity secondaries at Pantheon, to find out if GP-led CVs ...

Sanofi’s Tzield has been accepted for priority review by the U.S. Food and Drug Administration to expand its use to children aged one year and older with stage 2 type 1 diabetes. The submission is ...